eftozanermin alfa + bortezomib + dexamethasone

**Eftozanermin alfa + bortezomib + dexamethasone** is an investigational combination therapy being studied for the treatment of relapsed or refractory multiple myeloma. *Eftozanermin alfa* (ABBV-621) is a recombinant fusion protein agonist of the TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) death receptors, designed to induce apoptosis in cancer cells expressing these receptors. *Bortezomib* is a small molecule proteasome inhibitor that disrupts proteasomal protein degradation, leading to apoptosis in multiple myeloma cells. *Dexamethasone* is a synthetic glucocorticoid corticosteroid that exerts broad anti-inflammatory and immunosuppressive effects and is used in multiple myeloma regimens to decrease tumor burden and reduce inflammation. The combination is given to adults with relapsed/refractory multiple myeloma, aiming to enhance anti-myeloma activity through complementary mechanisms including apoptosis induction, proteasome inhibition, and immunomodulation. This regimen is in clinical phase evaluation and not yet approved, with studies focusing on establishing the recommended phase 2 dose and assessing disease symptom changes[2][4][6][8].

Other names

eftozanermin alfa + bortezomib + dexamethasone